ascopubs.org5d
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...
ascopubs.org5d
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...
ascopubs.org5d
A survival prediction model for veterans with advanced bladder cancer (BC) treated with immune checkpoint inhibitors (ICI).
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer. PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting ...
ascopubs.org5d
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ascopubs.org5d
Checkpoint blockade as neoadjuvant strategy: A single-arm meta-analysis of dual PD-1/PD-L1 and CTLA-4 inhibition in urothelial cancer.
Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis. Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients ...
ascopubs.org5d
Real-world prevalence and outcomes of androgen receptor ligand-binding domain mutations in prostate cancer.
Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC). Evaluating the association between bone pain and radiologic progression-free survival (rPFS) ...
ascopubs.org5d
Analysis of gene expression signatures in prostate cancer prior to liver metastases.
Impact of homologous recombination repair alterations (HRRalt) on survival outcomes of patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Effects of emerin dysregulation on the ...
ascopubs.org5d
Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.
Deciphering immune-genomic markers of hyperprogression in patients (Pts) with metastatic urothelial cancer (mUC) treated with immune checkpoint inhibitors (ICIs). This is an ASCO Meeting Abstract from ...
ascopubs.org5d
The comparison of clinical utility between pan-cancer panel and PCa-specific panel for mCRPC.
Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy. Barriers to ...
ascopubs.org5d
Survival in advanced prostate cancer (PCa) patients with visceral metastasis: A population-based SEER study.
Impact of androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy on health-related quality of life.
ascopubs.org5d
Characterization of genitourinary drug approvals by the FDA, 2020-2024.
Sarcopenia as a marker to assess the surveillance necessity after a 5-year cancer-free period in patients who undergo radical cystectomy: A multi-institutional retrospective study.
ascopubs.org4d
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer.
DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.